Alpha Wave Global LP Acquires Shares of 72,407 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Alpha Wave Global LP bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 72,407 shares of the medical equipment provider’s stock, valued at approximately $6,478,000. Lantheus accounts for approximately 3.0% of Alpha Wave Global LP’s investment portfolio, making the stock its 6th largest holding. Alpha Wave Global LP owned 0.10% of Lantheus as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new position in Lantheus during the fourth quarter valued at $36,183,000. Swedbank AB lifted its position in Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after acquiring an additional 385,000 shares during the period. Keybank National Association OH bought a new stake in Lantheus during the fourth quarter worth about $27,526,000. Norges Bank purchased a new stake in Lantheus in the fourth quarter worth about $26,189,000. Finally, Wellington Management Group LLP bought a new position in shares of Lantheus during the fourth quarter valued at approximately $20,022,000. Institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on LNTH. JMP Securities restated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial raised their price target on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Finally, B. Riley lowered their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.43.

Lantheus Price Performance

Lantheus stock opened at $101.32 on Friday. Lantheus Holdings, Inc. has a one year low of $61.47 and a one year high of $126.89. The business’s fifty day moving average is $95.00 and its 200 day moving average is $95.55. The stock has a market capitalization of $6.94 billion, a PE ratio of 16.86 and a beta of 0.20.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The company had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Activity

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock valued at $6,016,046 in the last ninety days. 1.50% of the stock is currently owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.